NCT04445389View on ClinicalTrials.gov

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 17, 2020

Primary Completion Date

December 17, 2020

Study Completion Date

December 17, 2020

Conditions
SARS-CoV-2
Interventions
DRUG

GX-19

DNA vaccine expressing SARS-CoV-2 S-protein antigen

DRUG

Saline

Saline

Trial Locations (1)

03722

Severance hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT04445389 - Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter